Lantern Pharma Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC clinical trial. The trial evaluates investigational drug candidate LP-300 in never-smoker non-small cell lung cancer patients, marking a significant advancement in addressing this specific cancer subtype.

The completion of enrollment in Japan ahead of schedule demonstrates excellent execution of the company's international expansion strategy and validates the decision to focus on regions where never-smoker NSCLC has the highest prevalence. This achievement builds momentum as the company continues enrollment in Taiwan and the United States, bringing it closer to generating clinical data that could establish LP-300 as a treatment option for this underserved patient population.

Lantern Pharma's proprietary AI and machine learning platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. The company's approach has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers.

The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. For more information about specialized communications in the biotechnology sector, visit https://www.BioMedWire.com. Full terms of use and disclaimers applicable to all content are available at https://www.BioMedWire.com/Disclaimer.